Latest Hotspot

Tharimmune Partners with Intract Pharma to Develop Oral Infliximab, Secures Global Rights

18 September 2024
3 min read

Tharimmune, Inc. (NASDAQ: THAR) (“Tharimmune”), a biotechnology firm in the clinical development stage focused on creating therapeutic candidates for inflammation and immunology, revealed that it has secured a definitive agreement with Intract Pharma. Under this exclusive licensing deal, Tharimmune will obtain rights to INT-023/TH023, an oral monoclonal antibody against tumor necrosis factor-alpha (TNF-α), known as infliximab. This significant collaboration is designed to broaden Tharimmunes therapeutic pipeline and strengthen its dedication to advancing novel treatments for autoimmune disorders.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

According to the agreement terms, Tharimmune has obtained the worldwide rights (excluding South Korea) to develop and market Intract Pharma’s delivery systems, Soteria® and Phloral®, as well as secured a pre-existing supply contract for infliximab to aid in the oral formulation development effort. Intract Pharma received an initial payment and stands to gain additional funds upon the Company’s equity financing. They will also benefit from future developmental, regulatory, and commercial milestones, in addition to mid-single digit royalties on the net sales of the product. The agreement maintains a first refusal right to proceed with development and commercialization after successfully completing a Phase 2 clinical trial. Tharimmune also has the opportunity to extend the license to Intract’s platform for up to four more targets.

Infliximab is a purified monoclonal antibody protein derived from recombinant DNA, featuring both murine and human elements that block TNF-α. TNF-α is a critical signaling protein linked to acute phase reactions and systemic inflammation. Janssen Biotech markets infliximab under the brand name Remicade® for various diseases, including Crohn’s disease, ulcerative colitis, rheumatoid conditions, and plaque psoriasis.

Administering antibodies like infliximab orally has traditionally been difficult due to the complexity of getting such large molecules through the gastrointestinal system. This new collaboration seeks to address these challenges by employing Intract’s delivery systems, potentially enabling infliximab to be taken in pill form. An oral delivery method has the potential to enhance patient adherence and quality of life, while decreasing the strain on healthcare systems caused by prolonged intravenous treatments.

“Incorporating Intract’s cutting-edge technology with the high-quality infliximab supplied through our existing agreement offers significant potential to expedite and strengthen our focus on immunology. This collaboration not only widens our therapeutic scope but also supports our mission to improve patient outcomes by creating more convenient and accessible treatments,” said Randy Milby, CEO of Tharimmune. “An oral form of infliximab marks a noteworthy progress in treating chronic inflammatory disorders and positions Tharimmune to compete in a large, global market.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

According to the data provided by the Synapse Database, As of September 18, 2024, there are 118 investigational drugs for the IL-12 target, including 123 indications, 159 R&D institutions involved, with related clinical trials reaching 300, and as many as 45390 patents.

The drug INT-023 is a monoclonal antibody that targets IL-12 and is being developed by Intract Pharma Ltd. The therapeutic areas of focus for this drug are immune system diseases and digestive system disorders, with a specific active indication for inflammatory bowel diseases. Currently, the highest phase of development for INT-023 is preclinical.

图形用户界面, 文本, 应用程序

描述已自动生成

Coya Therapeutics' COYA 302 Exhibits Anti-Inflammatory Effects in Brain with Subcutaneous Dose in Parkinson's Mouse Model
Latest Hotspot
3 min read
Coya Therapeutics' COYA 302 Exhibits Anti-Inflammatory Effects in Brain with Subcutaneous Dose in Parkinson's Mouse Model
18 September 2024
Coya Therapeutics Reports that Subcutaneously Dosed COYA 302 Shows Direct Anti-Inflammatory Effects in the Brain in a Mouse Model of Parkinson’s Disease.
Read →
Groundbreaking Biologic Dupixent Shows Promising Results in Bullous Pemphigoid Study
Latest Hotspot
3 min read
Groundbreaking Biologic Dupixent Shows Promising Results in Bullous Pemphigoid Study
15 September 2024
Dupixent, the pioneering biologic, has shown remarkable success in reducing symptoms and achieving disease remission in a pivotal study on bullous pemphigoid.
Read →
Encouraging Phase 1 Results for Nxera Pharma and Centessa's New Sleep Deprivation Drug, ORX750
Latest Hotspot
2 min read
Encouraging Phase 1 Results for Nxera Pharma and Centessa's New Sleep Deprivation Drug, ORX750
15 September 2024
Nxera Pharma's collaborator Centessa reveals encouraging interim Phase 1 clinical results for their new OX2R agonist, ORX750, in healthy volunteers with acute sleep deprivation.
Read →
FDA Approves TREMFYA® for Severe Ulcerative Colitis, Enhancing Johnson & Johnson's Market Position
Latest Hotspot
4 min read
FDA Approves TREMFYA® for Severe Ulcerative Colitis, Enhancing Johnson & Johnson's Market Position
15 September 2024
The U.S. FDA has approved TREMFYA® (guselkumab) for adults with moderate to severe ulcerative colitis, bolstering Johnson & Johnson's position in the inflammatory bowel disease market.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.